Palatin Technologies, Inc. (PTN: Quote), a New Jersey-based Pharma company, Friday said its partner AstraZeneca will stop all further development of the obesity drug AZD2820.
AZD2820, a clinical candidate under development by AstraZeneca with Palatin, was halted following a serious adverse event in its Phase I trial, subsequently followed by AstraZeneca' decision to discontinue its development.
In addition, Palatin said it was eligible for milestone payments, subject to certain development and regulatory milestones with further payments on achievement of sales targets.
Thursday, Palatin closed at $0.64 on the NYSE market.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org